Fecal Microbiota Transplantation plus Anti-PD-1 Is Safe in a First-line Setting

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2023年 / 13卷 / 09期
关键词：
D O I：
10.1158/2159-8290.CD-RW2023-109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fecal microbiota transplantation combined with anti-PD-1 is safe in melanoma in the first-line setting.
引用
收藏
页码：1957 / 1957
页数：1
相关论文
共 50 条
  • [1] Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
    Routy, Bertrand
    Lenehan, John G.
    Miller, Wilson H.
    Jamal, Rahima
    Messaoudene, Meriem
    Daisley, Brendan A.
    Hes, Cecilia
    Al, Kait F.
    Martinez-Gili, Laura
    Puncochar, Michal
    Ernst, Scott
    Logan, Diane
    Belanger, Karl
    Esfahani, Khashayar
    Richard, Corentin
    Ninkov, Marina
    Piccinno, Gianmarco
    Armanini, Federica
    Pinto, Federica
    Krishnamoorthy, Mithunah
    Figueredo, Rene
    Thebault, Pamela
    Takis, Panteleimon
    Magrill, Jamie
    Ramsay, LeeAnn
    Derosa, Lisa
    Marchesi, Julian R.
    Parvathy, Seema Nair
    Elkrief, Arielle
    Watson, Ian R.
    Lapointe, Rejean
    Segata, Nicola
    Haeryfar, S. M. Mansour
    Mullish, Benjamin H.
    Silverman, Michael S.
    Burton, Jeremy P.
    Vareki, Saman Maleki
    [J]. NATURE MEDICINE, 2023, 29 (08) : 2121 - +
  • [2] Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
    Bertrand Routy
    John G. Lenehan
    Wilson H. Miller
    Rahima Jamal
    Meriem Messaoudene
    Brendan A. Daisley
    Cecilia Hes
    Kait F. Al
    Laura Martinez-Gili
    Michal Punčochář
    Scott Ernst
    Diane Logan
    Karl Belanger
    Khashayar Esfahani
    Corentin Richard
    Marina Ninkov
    Gianmarco Piccinno
    Federica Armanini
    Federica Pinto
    Mithunah Krishnamoorthy
    Rene Figueredo
    Pamela Thebault
    Panteleimon Takis
    Jamie Magrill
    LeeAnn Ramsay
    Lisa Derosa
    Julian R. Marchesi
    Seema Nair Parvathy
    Arielle Elkrief
    Ian R. Watson
    Rejean Lapointe
    Nicola Segata
    S.M. Mansour Haeryfar
    Benjamin H. Mullish
    Michael S. Silverman
    Jeremy P. Burton
    Saman Maleki Vareki
    [J]. Nature Medicine, 2023, 29 : 2121 - 2132
  • [3] A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation
    Meng, Yiming
    Sun, Jing
    Zhang, Guirong
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 200
  • [4] Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
    Bertrand Routy
    John G. Lenehan
    Wilson H. Miller
    Rahima Jamal
    Meriem Messaoudene
    Brendan A. Daisley
    Cecilia Hes
    Kait F. Al
    Laura Martinez-Gili
    Michal Punčochář
    Scott Ernst
    Diane Logan
    Karl Belanger
    Khashayar Esfahani
    Corentin Richard
    Marina Ninkov
    Gianmarco Piccinno
    Federica Armanini
    Federica Pinto
    Mithunah Krishnamoorthy
    Rene Figueredo
    Pamela Thebault
    Panteleimon Takis
    Jamie Magrill
    LeeAnn Ramsay
    Lisa Derosa
    Julian R. Marchesi
    Seema Nair Parvathy
    Arielle Elkrief
    Ian R. Watson
    Rejean Lapointe
    Nicola Segata
    S.M. Mansour Haeryfar
    Benjamin H. Mullish
    Michael S. Silverman
    Jeremy P. Burton
    Saman Maleki Vareki
    [J]. Nature Medicine, 2024, 30 : 604 - 604
  • [5] Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.
    Park, Sook Ryun
    Kim, Gihyeon
    Kim, Yunjae
    Cho, Beomki
    Kim, Sang-Yeob
    Do, Eun-Ju
    Bae, Dong-Jun
    Kweon, Mi-Na
    Song, Joon Seon
    Park, Hansoo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor
    Kim, Yunjae
    Kim, Gihyeon
    Kim, Sujeong
    Cho, Beomki
    Kim, Sang-Yeob
    Do, Eun-Ju
    Bae, Dong-Jun
    Kim, Seungil
    Kweon, Mi-Na
    Song, Joon Seon
    Park, Sang Hyoung
    Hwang, Sung Wook
    Kim, Mi-Na
    Kim, Yeongmin
    Min, Kyungchan
    Kim, Sung-Han
    Adams, Mark D.
    Lee, Charles
    Park, Hansoo
    Park, Sook Ryun
    [J]. CELL HOST & MICROBE, 2024, 32 (08)
  • [7] Fecal microbiota transplantation followed by anti-PD-1 treatment in patients with advanced melanoma.
    Miller, Wilson H.
    Routy, Bertrand
    Jamal, Rahima
    Ernst, D. Scott
    Logan, Diane
    Esfahani, Khashayar
    Belanger, Karl
    Elkrief, Arielle
    Lapointe, Rejean
    Thebault, Pamela
    Ponce, Mayra
    Parvathy, Seema Nair
    Messaoudene, Meriem
    Silverman, Micheal
    Maleki, Saman
    Lenehan, John Gordon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Anti-PD-1 therapies—a new first-line option in advanced melanoma
    Ryan J. Sullivan
    Keith T. Flaherty
    [J]. Nature Reviews Clinical Oncology, 2015, 12 : 625 - 626
  • [9] Anti-PD-1 therapies- a new first-line option in advanced melanoma
    Sullivan, Ryan J.
    Flaherty, Keith T.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (11) : 625 - 626
  • [10] Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial (vol 29, pg 2121, 2023 )
    Routy, Bertrand
    Lenehan, John G.
    Miller Jr, Wilson H.
    Jamal, Rahima
    Messaoudene, Meriem
    Daisley, Brendan A.
    Hes, Cecilia
    Al, Kait F.
    Martinez-Gili, Laura
    Puncochar, Michal
    Ernst, Scott
    Logan, Diane
    Belanger, Karl
    Esfahani, Khashayar
    Richard, Corentin
    Ninkov, Marina
    Piccinno, Gianmarco
    Armanini, Federica
    Pinto, Federica
    Krishnamoorthy, Mithunah
    Figueredo, Rene
    Thebault, Pamela
    Takis, Panteleimon
    Magrill, Jamie
    Ramsay, Leeann
    Derosa, Lisa
    Marchesi, Julian R.
    Parvathy, Seema Nair
    Elkrief, Arielle
    Watson, Ian R.
    Lapointe, Rejean
    Segata, Nicola
    Haeryfar, S. M. Mansour
    Mullish, Benjamin H.
    Silverman, Michael S.
    Burton, Jeremy P.
    Vareki, Saman Maleki
    [J]. NATURE MEDICINE, 2024, 30 (03) : 604 - 604
12345